M&G Plc Makes New $20.72 Million Investment in Illumina, Inc. (NASDAQ:ILMN)

M&G Plc acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 151,229 shares of the life sciences company’s stock, valued at approximately $20,718,000. M&G Plc owned approximately 0.09% of Illumina at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. CCLA Investment Management grew its holdings in Illumina by 0.3% during the 1st quarter. CCLA Investment Management now owns 207,831 shares of the life sciences company’s stock worth $28,822,000 after acquiring an additional 678 shares during the last quarter. Sentry Investment Management LLC acquired a new position in shares of Illumina during the first quarter worth approximately $123,000. Dorsey & Whitney Trust CO LLC grew its stake in shares of Illumina by 8.7% during the first quarter. Dorsey & Whitney Trust CO LLC now owns 2,599 shares of the life sciences company’s stock valued at $357,000 after purchasing an additional 208 shares during the last quarter. Leo Wealth LLC acquired a new stake in shares of Illumina in the first quarter valued at approximately $207,000. Finally, Orion Portfolio Solutions LLC raised its position in Illumina by 10.4% in the 1st quarter. Orion Portfolio Solutions LLC now owns 7,918 shares of the life sciences company’s stock worth $1,087,000 after purchasing an additional 746 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on ILMN shares. Robert W. Baird lifted their target price on Illumina from $125.00 to $128.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Scotiabank cut their target price on shares of Illumina from $185.00 to $176.00 and set a “sector outperform” rating on the stock in a research report on Monday, May 6th. Jefferies Financial Group initiated coverage on shares of Illumina in a research note on Monday, June 3rd. They set a “hold” rating and a $115.00 price target for the company. Citigroup upgraded shares of Illumina from a “neutral” rating to a “buy” rating and set a $140.00 price objective on the stock in a report on Wednesday, July 10th. Finally, Royal Bank of Canada lowered their target price on shares of Illumina from $249.00 to $242.00 and set an “outperform” rating for the company in a report on Monday, July 1st. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $158.57.

Illumina Stock Down 1.1 %

Shares of Illumina stock traded down $1.30 during trading on Friday, reaching $114.49. The stock had a trading volume of 1,372,989 shares, compared to its average volume of 3,804,000. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $18.24 billion, a price-to-earnings ratio of -14.05 and a beta of 1.15. Illumina, Inc. has a 52 week low of $89.00 and a 52 week high of $195.64. The stock has a fifty day moving average price of $109.51 and a two-hundred day moving average price of $124.74.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.05 billion. During the same quarter in the prior year, the firm posted $0.08 EPS. The business’s revenue was down 1.0% on a year-over-year basis. Sell-side analysts predict that Illumina, Inc. will post 1.38 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.